Molecular targets for disrupting leukocyte trafficking during multiple sclerosis

Erin E. McCandless; Robyn S. Klein

doi:10.1017/S1462399407000397

Molecular targets for disrupting leukocyte trafficking during multiple sclerosis

Published online by Cambridge University Press: 19 July 2007

Erin E. McCandless and

Robyn S. Klein

Show author details

Erin E. McCandless: Affiliation:
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Robyn S. Klein*: Affiliation:
Departments of Pathology and Immunology, Internal Medicine, and Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO, USA.
*: *Corresponding author: Robyn S. Klein, Washington University School of Medicine, Departments of Internal Medicine, Infectious Diseases, Pathology and Immunology, and Anatomy and Neurobiology, Campus Box 8051, 660 S. Euclid Ave, St Louis, MO 63110, USA. Tel: +1 314 286 2140; Fax: +1 314 362 2190; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

Autoimmune diseases of the central nervous system (CNS) involve the migration of abnormal numbers of self-directed leukocytes across the blood–brain barrier that normally separates the CNS from the immune system. The cardinal lesion associated with neuroinflammatory diseases is the perivascular infiltrate, which comprises leukocytes that have traversed the endothelium and have congregated in a subendothelial space between the endothelial-cell basement membrane and the glial limitans. The exit of mononuclear cells from this space can be beneficial, as when virus-specific lymphocytes enter the CNS for pathogen clearance, or might induce CNS damage, such as in the autoimmune disease multiple sclerosis when myelin-specific lymphocytes invade and induce demyelinating lesions. The molecular mechanisms involved in the movement of lymphocytes through these compartments involve multiple signalling pathways between these cells and the microvasculature. In this review, we discuss adhesion, costimulatory, cytokine, chemokine and signalling molecules involved in the dialogue between lymphocytes and endothelial cells that leads to inflammatory infiltrates within the CNS, and the targeting of these molecules as therapies for the treatment of multiple sclerosis.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 9 , Issue 20 , July 2007 , pp. 1 - 19

DOI: https://doi.org/10.1017/S1462399407000397 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Butcher, E.C. and Picker, L.J. (1996) Lymphocyte homing and homeostasis. Science 272, 60-66CrossRef Google Scholar PubMed

2Springer, T.A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314CrossRef Google Scholar PubMed

3Johnston, B. and Butcher, E.C. (2002) Chemokines in rapid leukocyte adhesion triggering and migration. Semin Immunol 14, 83-92CrossRef Google Scholar PubMed

4Zollner, T.M., Asadullah, K. and Schon, M.P. (2007) Targeting leukocyte trafficking to inflamed skin - still an attractive therapeutic approach? Exp Dermatol 16, 1-12CrossRef Google Scholar PubMed

5Lucas, S.M., Rothwell, N.J. and Gibson, R.M. (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1, S232-240CrossRef Google Scholar

6Ballabh, P., Braun, A. and Nedergaard, M. (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16, 1-13CrossRef Google Scholar PubMed

7Frohman, E.M., Racke, M.K. and Raine, C.S. (2006) Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 354, 942-955CrossRef Google Scholar PubMed

8Sospedra, M. and Martin, R. (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23, 683-747CrossRef Google Scholar PubMed

9Prat, A. and Antel, J. (2005) Pathogenesis of multiple sclerosis. Curr Opin Neurol 18, 225-230CrossRef Google Scholar PubMed

10Siva, A. (2006) The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 108, 333-338CrossRef Google Scholar PubMed

11Huseby, E.S. et al. (2001) A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194, 669-676CrossRef Google Scholar

12Weaver, C.T. et al. (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677-688CrossRef Google Scholar PubMed

13Harrington, L.E. et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6, 1123-1132CrossRef Google Scholar

14Akbar, A.N. et al. (2007) The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 7, 231-237CrossRef Google Scholar PubMed

15Chen, Y. et al. (1994) Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240CrossRef Google Scholar PubMed

16Cua, D.J. et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748CrossRef Google Scholar PubMed

17Langrish, C.L. et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233-240CrossRef Google Scholar PubMed

18Bruck, W. et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38, 788-796CrossRef Google Scholar PubMed

19Huitinga, I. et al. (1990) Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 172, 1025-1033CrossRef Google Scholar PubMed

20Powell, N.D. et al. (2005) Cutting edge: macrophage migration inhibitory factor is necessary for progression of experimental autoimmune encephalomyelitis. J Immunol 175, 5611-5614CrossRef Google Scholar PubMed

21Denkinger, C.M. et al. (2003) In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 170, 1274-1282CrossRef Google Scholar PubMed

22Juedes, A.E. and Ruddle, N.H. (2001) Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol 166, 5168-5175CrossRef Google Scholar PubMed

23Laschinger, M. and Engelhardt, B. (2000) Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol 102, 32-43CrossRef Google Scholar

24Piccio, L. et al. (2002) Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors. J Immunol 168, 1940-1949CrossRef Google Scholar

25Piccio, L. et al. (2005) Efficient recruitment of lymphocytes in inflamed brain venules requires expression of cutaneous lymphocyte antigen and fucosyltransferase-VII. J Immunol 174, 5805-5813CrossRef Google Scholar PubMed

26Engelhardt, B. et al. (1997) E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 90, 4459-4472CrossRef Google Scholar

27Ubogu, E.E., Cossoy, M.B. and Ransohoff, R.M. (2006) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 27, 48-55CrossRef Google Scholar PubMed

28Engelhardt, B. (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 113, 477-485CrossRef Google Scholar

29Biernacki, K. et al. (2001) Regulation of Th1 and Th2 lymphocyte migration by human adult brain endothelial cells. J Neuropathol Exp Neurol 60, 1127-1136CrossRef Google Scholar PubMed

30Bullard, D.C. et al. (2007) Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J Immunol 178, 851-857CrossRef Google Scholar PubMed

31Floris, S. et al. (2002) Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 127, 69-79CrossRef Google Scholar PubMed

32Mahad, D. et al. (2006) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129, 212-223CrossRef Google Scholar PubMed

33Prat, A. et al. (2002) Migration of multiple sclerosis lymphocytes through brain endothelium. Arch Neurol 59, 391-397CrossRef Google Scholar PubMed

34Quandt, J. and Dorovini-Zis, K. (2004) The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J Neuropathol Exp Neurol 63, 350-362CrossRef Google Scholar PubMed

35McCandless, E.E. et al. (2006) CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 177, 8053-8064CrossRef Google Scholar

36Brocke, S. et al. (1999) Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 96, 6896-6901CrossRef Google Scholar

37Kent, S.J. et al. (1995) A monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 5, 535-540CrossRef Google Scholar PubMed

38Miller, D.H. et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348, 15-23CrossRef Google Scholar PubMed

39Tubridy, N. et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53, 466-472CrossRef Google Scholar PubMed

40Yednock, T.A. et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63-66CrossRef Google Scholar PubMed

41Adelman, B., Sandrock, A. and Panzara, M.A. (2005) Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 353, 432-433CrossRef Google Scholar PubMed

42Giunti, D. et al. (2003) Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol 73, 584-590CrossRef Google Scholar PubMed

43Misu, T. et al. (2001) Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 114, 207-212CrossRef Google Scholar

44Sorensen, T.L. and Sellebjerg, F. (2001) Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 57, 1371-1376CrossRef Google Scholar PubMed

45Sorensen, T.L. et al. (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103, 807-815CrossRef Google Scholar PubMed

46Tran, E.H., Kuziel, W.A. and Owens, T. (2000) Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 30, 1410-14153.0.CO;2-L>CrossRef Google Scholar PubMed

47Liu, L. et al. (2006) Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol 176, 4399-4409CrossRef Google Scholar PubMed

48Pulkkinen, K. et al. (2004) Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 109, 342-347CrossRef Google Scholar PubMed

49Bennetts, B.H. et al. (1997) The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58, 52-59CrossRef Google Scholar PubMed

50Favorova, O.O. et al. (2006) Three allele combinations associated with multiple sclerosis. BMC Med Genet 7, 63CrossRef Google Scholar PubMed

51Gade-Andavolu, R. et al. (2004) Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 6, 126-131CrossRef Google Scholar PubMed

52Kantarci, O.H. et al. (2005) CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 169, 137-143CrossRef Google Scholar PubMed

53Huang, D.R. et al. (2001) Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 193, 713-726CrossRef Google Scholar PubMed

54Izikson, L. et al. (2000) Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192, 1075-1080CrossRef Google Scholar

55Rottman, J.B. et al. (2000) Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 30, 2372-23773.0.CO;2-D>CrossRef Google Scholar PubMed

56Fife, B.T. et al. (2000) CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192, 899-905CrossRef Google Scholar PubMed

57Zipp, F. et al. (2006) Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 67, 1880-1883CrossRef Google Scholar PubMed

58Brodmerkel, C.M. et al. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 175, 5370-5378CrossRef Google Scholar PubMed

59Kappos, L. et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355, 1124-1140CrossRef Google Scholar PubMed

60Rosen, H. and Goetzl, E.J. (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5, 560-570CrossRef Google Scholar PubMed

61Youssef, S. et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84CrossRef Google Scholar PubMed

62Nath, N. et al. (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172, 1273-1286CrossRef Google Scholar

63Greenwood, J. et al. (2003) Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. Faseb J 17, 905-907CrossRef Google Scholar PubMed

64Mach, F. (2002) Toward a role for statins in immunomodulation. Mol Interv 2, 478-480CrossRef Google Scholar

65Neuhaus, O. et al. (2005) Putative mechanisms of action of statins in multiple sclerosis–comparison to interferon-beta and glatiramer acetate. J Neurol Sci 233, 173-177CrossRef Google Scholar PubMed

66Weber, M.S. et al. (2006) Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 178, 140-148CrossRef Google Scholar PubMed

67Bernot, D. et al. (2003) Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol 41, 316-324CrossRef Google Scholar PubMed

68Takeuchi, S. et al. (2000) Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 269, 97-102CrossRef Google Scholar PubMed

69Greenwood, J., Steinman, L. and Zamvil, S.S. (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6, 358-370CrossRef Google Scholar PubMed

70Etienne, S. et al. (1998) ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol 161, 5755-5761CrossRef Google Scholar PubMed

71Neuhaus, O. et al. (2005) Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs 19, 833-841CrossRef Google Scholar PubMed

72Kappos, L. et al. (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6, 1176-1182CrossRef Google Scholar

73Vandenbark, A.A. (2005) TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4 + CD25+ Treg cells. Curr Drug Targets Inflamm Allergy 4, 217-229CrossRef Google Scholar PubMed

74Howard, L.M. et al. (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 103, 281-290CrossRef Google Scholar

75Howard, L.M. et al. (2002) Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis. J Clin Invest 109, 233-241CrossRef Google Scholar PubMed

76Howard, L.M. and Miller, S.D. (2001) Autoimmune intervention by CD154 blockade prevents T cell retention and effector function in the target organ. J Immunol 166, 1547-1553CrossRef Google Scholar PubMed

77Kalunian, K.C. et al. (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46, 3251-3258CrossRef Google Scholar PubMed

78Dumont, F.J. (2002) IDEC-131. IDEC/Eisai. Curr Opin Investig Drugs 3, 725-734Google Scholar PubMed

79Tischner, D. et al. (2006) Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of multiple sclerosis. Brain 129, 2635-2647CrossRef Google Scholar

80Humphreys, I.R. et al. (2003) A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 198, 1237-1242CrossRef Google Scholar

81Carboni, S. et al. (2003) CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 145, 1-11CrossRef Google Scholar

82Sharief, M.K. (2002) Heightened intrathecal release of soluble CD137 in patients with multiple sclerosis. Eur J Neurol 9, 49-54CrossRef Google Scholar PubMed

83Sun, Y. et al. (2002) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 168, 1457-1465CrossRef Google Scholar

84Malfitano, A.M. et al. (2006) Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 171, 110-119CrossRef Google Scholar PubMed

85Croxford, J.L. and Miller, S.D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55,212. J Clin Invest 111, 1231-1240CrossRef Google Scholar PubMed

86Ni, X. et al. (2004) Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10, 158-164CrossRef Google Scholar

87Witting, A. et al. (2006) Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci U S A 103, 6362-6367CrossRef Google Scholar PubMed

88Cree, B.A. et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270-1272CrossRef Google Scholar PubMed

89Cross, A.H. et al. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180, 63-70CrossRef Google Scholar

90Broom, K.A. et al. (2005) MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain. J Cereb Blood Flow Metab 25, 204-216CrossRef Google Scholar PubMed

91Dousset, V. et al. (2006) MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 27, 1000-1005Google Scholar PubMed

92Larsson, H.B. et al. (1990) Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 16, 117-131CrossRef Google Scholar PubMed

93Wuerfel, J. et al. (2004) Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 127, 111-119CrossRef Google Scholar PubMed

94Gimenez, M.A., Sim, J.E. and Russell, J.H. (2004) TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J Neuroimmunol 151, 116-125CrossRef Google Scholar PubMed

95Probert, L. et al. (2000) TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 123, 2005-2019CrossRef Google Scholar PubMed

96Kassiotis, G. et al. (1999) TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 29, 774-7803.0.CO;2-T>CrossRef Google Scholar

97Eugster, H.P. et al. (1999) Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 29, 626-6323.0.CO;2-A>CrossRef Google Scholar PubMed

98Cannella, B. and Raine, C.S. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37, 424-435CrossRef Google Scholar PubMed

99Minagar, A. and Alexander, J.S. (2003) Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9, 540-549CrossRef Google Scholar PubMed

100Duran, I. et al. (1999) Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122, 2297-2307CrossRef Google Scholar PubMed

101Khoury, S.J. et al. (1999) Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology 53, 758-764CrossRef Google Scholar PubMed

102Rieckmann, P. et al. (2005) Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. J Neurol 252, 526-533CrossRef Google Scholar PubMed

103Rieckmann, P. et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44, 2367-2372CrossRef Google Scholar PubMed

104Lin, R. et al. (2006) Lovastatin reduces apoptosis and downregulates the CD40 expression induced by TNF-alpha in cerebral vascular endothelial cells. Curr Neurovasc Res 3, 41-47CrossRef Google Scholar PubMed

105Williams, K.C. et al. (1996) PECAM-1 (CD31) expression in the central nervous system and its role in experimental allergic encephalomyelitis in the rat. J Neurosci Res 45, 747-7573.0.CO;2-T>CrossRef Google Scholar PubMed

106Omari, K.M. and Dorovini-Zis, K. (2003) CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J Neuroimmunol 134, 166-178CrossRef Google Scholar PubMed

107Kieseier, B.C. et al. (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121, 159-166CrossRef Google Scholar PubMed

108Chiodoni, C. et al. (2006) Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 203, 2441-2450CrossRef Google Scholar PubMed

109Melter, M. et al. (2000) Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96, 3801-3808CrossRef Google Scholar PubMed

110Fainardi, E. et al. (2006) Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 12, 294-301CrossRef Google Scholar PubMed

111Avolio, C. et al. (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136, 46-53CrossRef Google Scholar PubMed

112Sellebjerg, F. and Sorensen, T.L. (2003) Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 61, 347-355CrossRef Google Scholar PubMed

113Clements, J.M. et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74, 85-94CrossRef Google Scholar PubMed

114Omari, K.M., Chui, R. and Dorovini-Zis, K. (2004) Induction of beta-chemokine secretion by human brain microvessel endothelial cells via CD40/CD40L interactions. J Neuroimmunol 146, 203-208CrossRef Google Scholar PubMed

115Harkness, K.A. et al. (2000) Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123, 698-709CrossRef Google Scholar PubMed

116Hawkins, B.T. et al. (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50, 202-211CrossRef Google Scholar PubMed

117Mori, T. et al. (2002) Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J Neurotrauma 19, 1411-1419CrossRef Google Scholar PubMed

118Reijerkerk, A. et al. (2006) Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. Faseb J 20, 2550-2552CrossRef Google Scholar PubMed

119Graesser, D. et al. (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 109, 383-392CrossRef Google Scholar PubMed

120Agrawal, S. et al. (2006) Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203, 1007-1019CrossRef Google Scholar PubMed

121Becher, B. et al. (2001) The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med 193, 967-974CrossRef Google Scholar PubMed

122Samoilova, E.B. et al. (1997) CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. J Mol Med 75, 603-608CrossRef Google Scholar

123Ponomarev, E.D., Shriver, L.P. and Dittel, B.N. (2006) CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J Immunol 176, 1402-1410CrossRef Google Scholar PubMed

124Nanki, T. et al. (2000) Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165, 6590-6598CrossRef Google Scholar PubMed

125Jung, Y. et al. (2006) Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 38, 497-508CrossRef Google Scholar PubMed

126Stumm, R.K. et al. (2002) A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci 22, 5865-5878CrossRef Google Scholar PubMed

127Akassoglou, K. et al. (2003) Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci U S A 100, 709-714CrossRef Google Scholar PubMed

128Engelhardt, B. (2000) Role of glucocorticoids on T cell recruitment across the blood-brain barrier. Z Rheumatol 59 Suppl 2: II/18–21CrossRef Google Scholar

129Trojano, M. et al. (1998) Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Mult Scler 4, 39-44CrossRef Google Scholar PubMed

130Engelhardt, B. et al. (2005) P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J Immunol 175, 1267-1275CrossRef Google Scholar

131Osmers, I., Bullard, D.C. and Barnum, S.R. (2005) PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. J Neuroimmunol 166, 193-196CrossRef Google Scholar

132Kerfoot, S.M. and Kubes, P. (2002) Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 169, 1000-1006CrossRef Google Scholar

133Auchampach, J.A. et al. (1994) Cloning, sequence comparison and in vivo expression of the gene encoding rat P-selectin. Gene 145, 251-255CrossRef Google Scholar PubMed

134Sanders, W.E. et al. (1992) Molecular cloning and analysis of in vivo expression of murine P-selectin. Blood 80, 795-800CrossRef Google Scholar PubMed

135Prasad, R. et al. (2006) 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction. J Neurosci Res 84, 614-625CrossRef Google Scholar PubMed

136Prasad, R. et al. (2007) GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia 55, 65-77CrossRef Google Scholar PubMed

137't Hart, B.A. et al. (2005) Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 163, 31-39CrossRef Google Scholar PubMed

138Allen, S.D. et al. (2005) Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 65, 591-604CrossRef Google Scholar PubMed

139Subramanian, S. et al. (2003) Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 170, 1548-1555CrossRef Google Scholar PubMed

140Matejuk, A. et al. (2004) Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res 77, 119-126CrossRef Google Scholar PubMed

141Polanczyk, M. et al. (2003) The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol 163, 1599-1605CrossRef Google Scholar PubMed

142Morales, L.B. et al. (2006) Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 26, 6823-6833CrossRef Google Scholar PubMed

143Matejuk, A. et al. (2003) 17Beta-estradiol treatment profoundly down-regulates gene expression in spinal cord tissue in mice protected from experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz) 51, 185-193Google Scholar PubMed

144Kremenchutzky, M., Morrow, S. and Rush, C. (2007) The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin Drug Saf 6, 279-288CrossRef Google Scholar PubMed

145Perini, P. et al. (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6, 183-190CrossRef Google Scholar PubMed

146Perumal, J. et al. (2006) Glatiramer acetate therapy for multiple sclerosis: a review. Expert Opin Drug Metab Toxicol 2, 1019-1029CrossRef Google Scholar PubMed

147Zaffaroni, M., Ghezzi, A. and Comi, G. (2006) Intensive immunosuppression in multiple sclerosis. Neurol Sci 27 Suppl 1, S13-17CrossRef Google Scholar PubMed

Article contents

Molecular targets for disrupting leukocyte trafficking during multiple sclerosis

Abstract

Access options

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Molecular targets for disrupting leukocyte trafficking during multiple sclerosis

Abstract

Access options

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests